Who We Are?
Sarcomatrix is a clinical stage rare disease pharmaceutical company dedicated to developing transformative, life-changing therapies for muscle-wasting diseases, including Duchenne Muscular Dystrophy (DMD), sarcopenia, and cachexia.
What We Believe, Mission & Vision
Our mission is to lead scientific innovation in rare muscle disease treatment, addressing urgent therapeutic needs, and to set a new global benchmark as pioneers in muscle health and regeneration. We are on a crusade to reclaim lives lost to these diseases, driven by meaningful, patient-centric breakthroughs that improve quality of life, believing no one should be left behind.
Our History
Leveraging decades of groundbreaking research from the Burkin Lab at the University of Nevada, Reno, Strykagen—a research spin-off- The exclusive research partner for Sarcomatrix, a Delaware C corporation holding exclusive development and commercialization rights.
